Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019

12:05 EDT 17 Apr 2019 | Businesswire

Dr. Reddy's Laboratories Ltd.

Earnings call slated for May 17, 6:00 PM IST / 8:30 AM EDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the fourth quarter and full year ended March 31, 2019 on Friday, May 17, 2019 after the Board Meeting.

Summary of Events

Event   Date and Time   Medium
Release of financial results   May 17th, after the Board Meeting  

Email, Media, Company website, Business Wire

Press meet presentation


Will be available on the Company’s website


URL available on Company’s website,

Earnings Call   May 17th, 6:00 PM IST / 8:30 AM EDT  

Hosted by the Company (Details below)

Playback of Earnings Call   After the earnings call till May 24th, 2019   Details below
Transcript of the Earnings call   Will be available on the Company’s website  

URL available on Company’s website,

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Play Back

The play back will be available after the earnings call, till May 24th, 2019. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and Playback Code is 04147.

Conference Dial-In Numbers
Universal Access Number:   +91 22 6280 1219

+91 22 7115 8120

Local Access Number:

Available all over India

  +91 70456 71221
International Toll Free Number:   USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to:

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency/severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

(Ph: +91-40-49002135)

(Ph: +91-40-49002121)


More From BioPortfolio on "Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019"

Quick Search


Relevant Topic

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...